Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
AU2015275086B2 - Quantitative analysis of transgenic proteins - Google Patents
[go: Go Back, main page]

AU2015275086B2 - Quantitative analysis of transgenic proteins - Google Patents

Quantitative analysis of transgenic proteins Download PDF

Info

Publication number
AU2015275086B2
AU2015275086B2 AU2015275086A AU2015275086A AU2015275086B2 AU 2015275086 B2 AU2015275086 B2 AU 2015275086B2 AU 2015275086 A AU2015275086 A AU 2015275086A AU 2015275086 A AU2015275086 A AU 2015275086A AU 2015275086 B2 AU2015275086 B2 AU 2015275086B2
Authority
AU
Australia
Prior art keywords
ala
val
gly
leu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015275086A
Other versions
AU2015275086A1 (en
Inventor
Jeffrey R. Gilbert
Ryan Christopher HILL
Trent James OMAN
Barry W. Schafer
Guomin Shan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corteva Agriscience LLC
Original Assignee
Dow AgroSciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow AgroSciences LLC filed Critical Dow AgroSciences LLC
Publication of AU2015275086A1 publication Critical patent/AU2015275086A1/en
Application granted granted Critical
Publication of AU2015275086B2 publication Critical patent/AU2015275086B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91045—Acyltransferases (2.3)
    • G01N2333/91051—Acyltransferases other than aminoacyltransferases (general) (2.3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/9116—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • G01N2333/91165—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5) general (2.5.1)
    • G01N2333/91171—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5) general (2.5.1) with definite EC number (2.5.1.-)
    • G01N2333/91182—Enolpyruvylshikimate-phosphate synthases (2.5.1.19)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)

Abstract

The invention relates to methods for quantitative multiplex analysis of complex protein samples from plants using mass spectroscopy. In some embodiments, the disclosure concerns methods for maintaining a transgenic plant variety, for example by analyzing generations of a transgenic plant variety for selective and sensitive quantitation of multiplexed transgenic proteins.

Description

The invention relates to methods for quantitative multiplex analysis of complex protein samples from plants using mass spectroscopy. In some embodiments, the disclosure concerns methods for maintaining a transgenic plant variety, for example by analyzing generations of a transgenic plant variety for selective and sensitive quantitation of multiplexed transgenic proteins.
1001990974
2015275086 23 Nov 2017
QUANTITATIVE ANALYSIS OF TRANSGENIC PROTEINS
BACKGROUND OF THE INVENTION [0001] Reference to any prior art in the specification is not an acknowledgment or suggestion that this prior art forms part of the common general knowledge in any jurisdiction or that this prior art could reasonably be expected to be understood, regarded as relevant, and/or combined with other pieces of prior art by a skilled person in the art.
[0001a] The increasing use of recombinant DNA technology to produce transgenic plants for commercial and industrial use requires the development of high-throughput methods of analyzing transgenic plant lines. Such analytical methods are needed for trait discovery research, product development, seed production, and commercialization and to assist in the rapid development of transgenic plants with desirable or optimal phenotypes. Moreover, current guidelines for the safety assessment of GM plants proposed for human consumption requires characterization at the DNA and protein level between the parent and transformed crop. New plant varieties that are developed consist of increasingly complex genetic modifications including, inter alia, stacked genes, and traits.
[0002] The current methods for analysis of transgenic plants that are preferred in the art include DNA-based techniques (for example PCR and/or RT-PCR); the use of reporter genes; Southern blotting; and immunochemistry. All of these methodologies suffer from various shortcomings.
[0003] Although mass spectrometry has been disclosed previously, existing approaches are limited without selected and sensitive quantitation. There remains a need for a highthroughput method for selected and sensitive quantitation of products of transgene expression in plants.
SUMMARY OF THE INVENTION [0004] The invention relates to methods for quantitative multiplex analysis of complex protein samples from plants using mass spectroscopy. In some embodiments, the disclosure concerns methods for maintaining a transgenic plant variety, for example by analyzing generations of a transgenic plant variety for selective and sensitive quantitation of multiplexed transgenic proteins.
[0005] In one aspect, provided is a high-throughput method of quantitating one or more protein of interest with known amino acid sequence in a plant-based sample. The method comprises:
1001990974
2015275086 23 Nov 2017 (a) extracting proteins from a plant-based sample;
(b) digesting proteins extracted from step (a) to obtain peptides;
(c) separating the peptides in a single step;
(d) determining a plural of signature peptides from the protein of interest with known amino acid sequence;
1A
WO 2015/191270
PCT/US2015/032155 (e) measuring the plural of signature peptides using high resolution accurate mass spectrometry (HRAM MS); and (f) quantitating the protein of interest with known amino acid sequence based on measurements of the signature peptides.
[0006] In one embodiment, the peptides are separated in a single step by column chromatography. In a further embodiment, the column chromatography comprises a liquid column chromatography. In another embodiment, mass spectral data for the peptides corresponding to the protein of interest are obtained in a single step.
[0007] In one embodiment, the one or more protein of interest comprises two proteins of interest. In another embodiment, the one or more protein of interest comprises three to twenty proteins of interest. In another embodiment, the one or more protein of interest comprises three to ten proteins of interest. In another embodiment, the one or more protein of interest comprises four proteins of interest.
[0008] In one embodiment, the plant-based sample is from a transgenic plant. In a further embodiment, the one or more protein of interest comprises expected product of transgene expression in the transgenic plant. In another embodiment, the one or more protein of interest comprises a 5’-enolpyruvyl-3’-phosphoshikimate synthase (EPSPS). In another embodiment, the one or more protein of interest comprises 5-enolpyruvylshikimate-3phosphate synthase (2mEPSPS). In another embodiment, the plural of signature peptides comprises at least one sequence selected from the group consisting of SEQ ID NOs: 2-25. In another embodiment, the plural of signature peptides comprises at least two sequences selected from the group consisting of SEQ ID NOs: 2-25. In another embodiment, the plural of signature peptides comprises at least three sequences selected from the group consisting of SEQ ID NOs: 2-25. In another embodiment, the plural of signature peptides comprises SEQ ID NOs 3, 12, and 21. In another embodiment, the plural of signature peptides consist of SEQ ID NOs 3, 12, and 21.
[0009] In another embodiment, the one or more protein of interest comprises an aryloxyalkanoate dioxygenase (AAD). In another embodiment, the one or more protein of interest comprises aryloxyalkanoate dioxygenase-12 (AAD-12). In another embodiment, the plural of signature peptides comprises at least one sequence selected from the group consisting of SEQ ID NOs: 27-45. In another embodiment, the plural of signature peptides comprises at least two sequences selected from the group consisting of SEQ ID NOs: 27-45.
In another embodiment, the plural of signature peptides comprises at least three sequences selected from the group consisting of SEQ ID NOs: 27-45. In another embodiment, the
WO 2015/191270
PCT/US2015/032155 plural of signature peptides comprises SEQ ID NOs 28, 29, and 34. In another embodiment, the plural of signature peptides consist of SEQ ID NOs 28, 29, and 34.
[0010] In another embodiment, the one or more protein of interest comprises a bialaphos resistance (bar) gene product or phosphinothricin N-acetyltransferase (PAT) enzyme. In another embodiment, the one or more protein of interest comprises phosphinothricin acetyltransferase (PAT). In another embodiment, the plural of signature peptides comprises at least one sequence selected from the group consisting of SEQ ID NOs: 47-60. In another embodiment, the plural of signature peptides comprises at least two sequences selected from the group consisting of SEQ ID NOs: 47-60. In another embodiment, the plural of signature peptides comprises at least three sequences selected from the group consisting of SEQ ID NOs: 47-60. In another embodiment, the plural of signature peptides comprises SEQ ID NOs 49, 55, and 56. In another embodiment, the plural of signature peptides consist of SEQ ID NOs 49, 55, and 56.
[0011] In one embodiment, measuring the plural of signature peptides comprises calculating corresponding peak heights or peak areas. In another embodiment, measuring the plural of signature peptides comprises comparing data from high fragmentation mode and low fragmentation mode.
[0012] In another aspect, provided is a high-throughput system for quantitating one or more protein of interest with known amino acid sequence in a plant-based sample. The system comprises:
(a) a high-throughput means for extracting proteins from a plant-based sample;
(b) a separation module for separating peptides in a single step;
(c) a selection module for selecting a plural of signature peptides from the protein of interest with known amino acid sequence; and (d) a high resolution accurate mass spectrometry (HRAM MS) for measuring the plural of signature peptides.
[0013] In one embodiment, the separation module comprises a column chromatography.
In another embodiment, the column chromatography comprises a liquid column chromatography. In another embodiment, the high resolution accurate mass spectrometry (HRAM MS) comprises a tandem mass spectrometer. In another embodiment, the high resolution accurate mass spectrometry (HRAM MS) does not comprise a tandem mass spectrometer.
[0014] In one embodiment, the plant-based sample is from a transgenic plant. In a further embodiment, the one or more protein of interest comprises expected product of transgene
WO 2015/191270
PCT/US2015/032155 expression in the transgenic plant. In another embodiment, the one or more protein of interest comprises a 5’-enolpyruvyl-3’-phosphoshikimate synthase (EPSPS). In another embodiment, the one or more protein of interest comprises 5-enolpyruvylshikimate-3phosphate synthase (2mEPSPS). In another embodiment, the plural of signature peptides comprises at least one sequence selected from the group consisting of SEQ ID NOs: 2-25. In another embodiment, the plural of signature peptides comprises at least two sequences selected from the group consisting of SEQ ID NOs: 2-25. In another embodiment, the plural of signature peptides comprises at least three sequences selected from the group consisting of SEQ ID NOs: 2-25. In another embodiment, the plural of signature peptides comprises SEQ ID NOs 3, 12, and 21. In another embodiment, the plural of signature peptides consist of SEQ ID NOs 3, 12, and 21.
[0015] In another embodiment, the one or more protein of interest comprises an aryloxyalkanoate dioxygenase (AAD). In another embodiment, the one or more protein of interest comprises aryloxyalkanoate dioxygenase-12 (AAD-12). In another embodiment, the plural of signature peptides comprises at least one sequence selected from the group consisting of SEQ ID NOs: 27-45. In another embodiment, the plural of signature peptides comprises at least two sequences selected from the group consisting of SEQ ID NOs: 27-45. In another embodiment, the plural of signature peptides comprises at least three sequences selected from the group consisting of SEQ ID NOs: 27-45. In another embodiment, the plural of signature peptides comprises SEQ ID NOs 28, 29, and 34. In another embodiment, the plural of signature peptides consist of SEQ ID NOs 28, 29, and 34.
[0016] In another embodiment, the one or more protein of interest comprises a bialaphos resistance (bar) gene product or phosphinothricin N-acetyltransferase (PAT) enzyme. In another embodiment, the one or more protein of interest comprises phosphinothricin acetyltransferase (PAT). In another embodiment, the plural of signature peptides comprises at least one sequence selected from the group consisting of SEQ ID NOs: 47-60. In another embodiment, the plural of signature peptides comprises at least two sequences selected from the group consisting of SEQ ID NOs: 47-60. In another embodiment, the plural of signature peptides comprises at least three sequences selected from the group consisting of SEQ ID NOs: 47-60. In another embodiment, the plural of signature peptides comprises SEQ ID NOs 49, 55, and 56. In another embodiment, the plural of signature peptides consist of SEQ ID NOs 49, 55, and 56.
[0017] In another aspect, provided is a high-throughput method of quantitating one or more protein of interest with known amino acid sequence in a plant-based sample. The
WO 2015/191270
PCT/US2015/032155 method comprises using the system provided herein.
BRIEF DESCRIPTION OF THE FIGURES [0018] FIG. 1 shows a representative analysis work flow for the methods and systems disclosed herein.
[0019] FIG. 2 shows another representative data from HRAM LC-MS for Standard Chromatogram 500 ng/mL Synthetic Peptide: total ion current (first panel from the top); combined extracted ion (second panel from the top); extracted ion 367.2082 m/z - EISGTVK (2+) (third panel from the top or the middle panel); extracted ion 367.1850 m/z - DVASWR (2+) (second panel from the bottom); and extracted ion 484.7798 m/z - VNGIGGLPGGK (2+) (first panel from the bottom). Extracted window is 2.0 ppm for all ions.
[0020] FIG. 3 shows representative data from HRAM LC-MS for Trypsin Digested Transgenic Soybean Sample Chromatogram: total ion current (first panel from the top); combined extracted ion (second panel from the top); extracted ion 367.2082 m/z - EISGTVK (2+) (third panel from the top or the middle panel); extracted ion 367.1850 m/z - DVASWR (2+) (second panel from the bottom); and extracted ion 484.7798 m/z - VNGIGGLPGGK (2+) (first panel from the bottom). Extracted window is 2.0 ppm for all ions.
[0021] FIG. 4 shows representative date of stacked HRAM LC-MS Standard (upper panel) and Transgenic (lower panel) Extracted Ion Chromatograms with peptide annotation for quantitation. Extracted window is 2.0 ppm for all ions.
[0022] FIG. 5 shows another representative data from HRAM LC-MS for Standard Chromatogram 500 ng/mL Synthetic Peptide: total ion current (first panel from the top); combined extracted ion (second panel from the top); extracted ion 346.6889 m/z - FGAIER (2+) (third panel from the top or the middle panel); extracted ion 621.8563 m/z IGGGDIVAISNVK (2+) (second panel from the bottom); and extracted ion 598.2831 m/z AAYDALDEATR (2+) (first panel from the bottom). Extracted window is 2.0 ppm for all ions.
[0023] FIG. 6 shows representative data from HRAM LC-MS for Trypsin Digested Transgenic Soybean Sample Chromatogram: total ion current (first panel from the top); combined extracted ion (second panel from the top); extracted ion 346.6889 m/z - FGAIER (2+) (third panel from the top or the middle panel); extracted ion 621.8563 m/z IGGGDIVAISNVK (2+) (second panel from the bottom); and extracted ion 598.2831 m/z AAYDALDEATR (2+) (first panel from the bottom). Extracted window is 2.0 ppm for all ions.
[0024] FIG. 7 shows representative date of stacked HRAM LC-MS Standard (upper
1001990974
ΓΟ
CM >
Ο
Ζ
CD
CM
NO
Ο m
cCM m
o
CM panel) and Transgenic (lower panel) Extracted Ion Chromatograms with peptide annotation for quantitation. Extracted window is 2.0 ppm for all ions [0025] FIG. 8 shows another representative data from E1RAM LC-MS for Standard Chromatogram 500 ng/mL Synthetic Peptide: total ion current (first panel from the top); combined extracted ion (second panel from the top); extracted ion 928.9367 m/z TEPQTPQEWIDDLER (2+) (third panel from the top or the middle panel); extracted ion 761.9330 m/z - SVVAVIGLPNDPSVR (2+) (second panel from the bottom); and extracted ion 565.8013 m/z - LHEALGYTAR (2+) (first panel from the bottom). Extracted window is 2.0 ppm for all ions.
[0026] FIG. 9 shows representative data from HRAM LC-MS for Trypsin Digested Transgenic Soybean Sample Chromatogram: total ion current (first panel from the top); combined extracted ion (second panel from the top); extracted ion 928.9367 m/z TEPQTPQEWIDDLER (2+) (third panel from the top or the middle panel); extracted ion 761.9330 m/z - SVVAVIGLPNDPSVR (2+) (second panel from the bottom); and extracted ion 565.8013 m/z - LHEALGYTAR (2+) (first panel from the bottom). Extracted window is 2.0 ppm for all ions.
[0027] FIG. 10 shows representative date of stacked HRAM LC-MS Standard (upper panel) and Transgenic (lower panel) Extracted Ion Chromatograms with peptide annotation for quantitation. Extracted window is 2.0 ppm for all ions.
DETAILED DESCRIPTION OF THE INVENTION [0027a] As used herein, except where the context requires otherwise, the term comprise and variations of the term, such as comprising, comprises and comprised, are not intended to exclude other additives, components, integers or steps.
[0028] This invention is based on the discovery that selected signature peptides from precursor proteins can generate sensitive quantitation during multiplex analysis with particular instrumentation. Specifically in one embodiment, a liquid chromatography coupled to high resolution accurate mass spectrometry (LC-HRAM MS) method to detect protein expression levels of 5-enolpyruvylshikimate-3-phosphate synthase (2mEPSPS). The methods and systems disclosed herein are capable of analyzing 2mEPSPS by itself or combined with additional proteins for a multiplexing assay for quantitative analysis in plant extracts. Specifically in another embodiment, a liquid chromatography coupled to high resolution accurate mass spectrometry (LC-HRAM MS) method to detect protein expression levels of aryloxyalkanoate dioxygenase-12 (AAD-12). The methods and systems disclosed herein are capable of analyzing AAD-12 by itself or combined with additional proteins for a
1001990974
2015275086 23 Nov 2017 multiplexing assay for quantitative analysis in plant extracts. Specifically in yet another embodiment, a liquid chromatography coupled to high resolution accurate mass spectrometry (LC-HRAM MS) method to detect protein expression levels of phosphinothricin
6A
WO 2015/191270
PCT/US2015/032155 acetyltransferase (PAT). The methods and systems disclosed herein are capable of analyzing PAT by itself or combined with additional proteins for a multiplexing assay for quantitative analysis in plant extracts.
[0029] It is of significance to have a sensitive multiplex assay that is capable of selectively detecting multiple transgenic proteins of interest due to increasing numbers of transgenic proteins being co-expressed or “stacked” to achieve tolerance to multiple herbicides or to provide multiple modes of action to insect resistance. Currently, all relevant technologies for transgenic protein expression detection rely heavily on traditional immunochemistry technologies which present a challenge to accommodate the volume of data required to generate per sample.
[0030] The mass spectrometry detection for quantitative studies is typically accomplished using selected reaction monitoring (SRM). Using particular type of instrumentation, initial mass-selection of ion of interest formed in the source, followed by, dissociation of this precursor (protein) ion in the collision region of the mass spectrometer (MS), then massselection, and counting, of a specific product (peptide) ion. In some embodiment, counts per unit time may provide an integratable peak area from which amounts or concentration of analytes can be determined. In some embodiment, the use of high resolution accurate mass (HRAM) monitoring for quantitation, performed on a HRAM capable mass spectrometer, may include, but is not limited to, hybrid quadrupole-time-of-flight, quadrupole-orbitrap, ion trap-orbitrap, or quadrupole-ion-trap-orbitrap (tribrid) mass spectrometers. Using particular type of instrumentation, peptides are not subject to fragmentation conditions, but rather are measured as intact peptides using full scan or targeted scan modes (for example selective ion monitoring mode or SIM). Integratable peak area can be determined by generating an extracted ion chromatogram for each specific analyte and amounts or concentration of analytes can be calculated. The high resolution and accurate mass nature of the data enable highly specific and sensitive ion signals for the analyte (protein and/or peptide) of interest. [0031] Unless otherwise stated, the following terms used in this application, including the specification and claims, have the definitions given below. It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise.
[0032] As used herein, the term “bioconfinement” refers to restriction of the movement of genetically modified plants or their genetic material to designated areas. The term includes physical, physicochemical, biological confinement, as well as other forms of confinement that prevent the survival, spread or reproduction of a genetically modified plants in the
WO 2015/191270
PCT/US2015/032155 natural environment or in artificial growth conditions.
[0033] As used herein, the term “complex protein sample” is used to distinguish a sample from a purified protein sample. A complex protein sample contains multiple proteins, and may additionally contain other contaminants.
[0034] As used herein, the general term “mass spectrometry” or “MS” refers to any suitable mass spectrometry method, device or configuration including, e.g., electrospray ionization (ESI), matrix-assisted laser desorption/ionization (MALDI) MS, MALDI-time of flight (TOF) MS, atmospheric pressure (AP) MALDI MS, vacuum MALDI MS, or combinations thereof. Mass spectrometry devices measure the molecular mass of a molecule (as a function of the molecule's mass-to-charge ratio) by measuring the molecule's flight path through a set of magnetic and electric fields. The mass-to-charge ratio is a physical quantity that is widely used in the electrodynamics of charged particles. The mass-to-charge ratio of a particular peptide can be calculated, a priori, by one of skill in the art. Two particles with different mass-to-charge ratio will not move in the same path in a vacuum when subjected to the same electric and magnetic fields.
[0035] Mass spectrometry instruments consist of three modules: an ion source, which splits the sample molecules into ions; a mass analyzer, which sorts the ions by their masses by applying electromagnetic fields; and a detector, which measures the value of an indicator quantity and thus provides data for calculating the abundances of each ion present. The technique has both qualitative and quantitative applications. These include identifying unknown compounds, determining the isotopic composition of elements in a molecule, determining the structure of a compound by observing its fragmentation, and quantifying the amount of a compound in a sample.
[0036] A detailed overview of mass spectrometry methodologies and devices can be found in the following references which are hereby incorporated by reference: Can and Annan (1997) Overview of peptide and protein analysis by mass spectrometry. In: Current Protocols in Molecular Biology, edited by Ausubel, et al. New York: Wiley, p. 10.21. ΙΙΟ.21.27; Paterson and Aebersold (1995) Electrophoresis 16: 1791-1814; Patterson (1998) Protein identification and characterization by mass spectrometry. In: Current Protocols in Molecular Biology, edited by Ausubel, et al. New York: Wiley, p. 10.22.1-10.22.24; and Domon and Aebersold (2006) Science 312(5771):212-17.
[0037] As the term is used herein, proteins and/or peptides are “multiplexed” when two or more proteins and/or peptides of interest are present in the same sample.
[0038] As used herein, a “plant trait” may refer to any single feature or quantifiable
WO 2015/191270
PCT/US2015/032155 measurement of a plant.
[0039] As used herein, the phrase “peptide” or peptides” may refer to short polymers formed from the linking, in a defined order, of α-amino acids. Peptides may also be generated by the digestion of polypeptides, for example proteins, with a protease.
[0040] As used herein, the phrase “protein” or proteins” may refer to organic compounds made of amino acids arranged in a linear chain and joined together by peptide bonds between the carboxyl and amino groups of adjacent amino acid residues. The sequence of amino acids in a protein is defined by the sequence of a gene, which is encoded in the genetic code. In general, the genetic code specifies 20 standard amino acids, however in certain organisms the genetic code can include selenocysteine—and in certain archaea-pyrrolysine. The residues in a protein are often observed to be chemically modified by post-translational modification, which can happen either before the protein is used in the cell, or as part of control mechanisms. Protein residues may also be modified by design, according to techniques familiar to those of skill in the art. As used herein, the term “protein” encompasses linear chains comprising naturally occurring amino acids, synthetic amino acids, modified amino acids, or combinations of any or all of the above.
[0041] As used herein, the term “single injection” refers to the initial step in the operation of a MS or LC-MS device. When a protein sample is introduced into the device in a single injection, the entire sample is introduced in a single step.
[0042] As used herein, the phrase “signature peptide” refers an identifier (short peptide) sequence of a specific protein. Any protein may contain an average of between 10 and 100 signature peptides. Typically signature peptides have at least one of the following criteria: easily detected by mass spectroscopy, predictably and stably eluted from a liquid chromatography (LC) column, enriched by reversed phase high performance liquid chromatography (RP-HPLC), good ionization, good fragmentation, or combinations thereof. A peptide that is readily quantified by mass spectrometry typically has at least one of the following criteria: readily synthesized, ability to be highly purified (>97%), soluble in ^20% acetonitrile, low non-specific binding, oxidation resistant, post-synthesis modification resistant, and a hydrophobicity or hydrophobicity index ^10 and 40. The hydrophobicity index can be calculated according to Krokhin, Molecular and Cellular Proteomics 3 (2004) 908, which is incorporated by reference. It’s known that a peptide having a hydrophobicity index less than 10 or greater than 40 may not be reproducibly resolved or eluted by a RPHPLC column.
[0043] As used herein, the term “stacked” refers to the presence of multiple heterologous
WO 2015/191270
PCT/US2015/032155 polynucleotides incorporated in the genome of a plant.
[0044] Tandem mass spectrometry: In tandem mass spectrometry, a parent ion generated from a molecule of interest may be filtered in a mass spectrometry instrument, and the parent ion subsequently fragmented to yield one or more daughter ions that are then analyzed (detected and/or quantified) in a second mass spectrometry procedure. In some embodiments, the use of tandem mass spectrometry is excluded. In these embodiments, tandem mass spectrometry is not used in the methods and systems provided. Thus, neither parent ions nor daughter ions are generated in these embodiments.
[0045] As used herein, the term “transgenic plant” includes reference to a plant which comprises within its genome a heterologous polynucleotide. Generally, the heterologous polynucleotide is stably integrated within the genome such that the polynucleotide is passed on to successive generations. The heterologous polynucleotide may be integrated into the genome alone or as part of a recombinant expression cassette. “Transgenic” is used herein to include any cell, cell line, callus, tissue, plant part or plant, the genotype of which has been altered by the presence of heterologous nucleic acid including those transgenic plants initially so altered as well as those created by sexual crosses or asexual propagation from the initial transgenic plant.
[0046] Any plants that provide useful plant parts may be treated in the practice of the present invention. Examples include plants that provide flowers, fruits, vegetables, and grains.
[0047] As used herein, the phrase “plant” includes dicotyledonous plants and monocotyledonous plants. Examples of dicotyledonous plants include tobacco, Arabidopsis, soybean, tomato, papaya, canola, sunflower, cotton, alfalfa, potato, grapevine, pigeon pea, pea, Brassica, chickpea, sugar beet, rapeseed, watermelon, melon, pepper, peanut, pumpkin, radish, spinach, squash, broccoli, cabbage, carrot, cauliflower, celery, Chinese cabbage, cucumber, eggplant, and lettuce. Examples of monocotyledonous plants include com, rice, wheat, sugarcane, barley, rye, sorghum, orchids, bamboo, banana, cattails, lilies, oat, onion, millet, and triticale. Examples of fruit include banana, pineapple, oranges, grapes, grapefruit, watermelon, melon, apples, peaches, pears, kiwifruit, mango, nectarines, guava, persimmon, avocado, lemon, fig, and berries. Examples of flowers include baby’s breath, carnation, dahlia, daffodil, geranium, gerbera, lily, orchid, peony, Queen Anne’s lace, rose, snapdragon, or other cut-flowers or ornamental flowers, potted-flowers, and flower bulbs.
[0048] The specificity allowed in a mass spectrometry approach for identifying a single protein from a complex sample is unique in that only the sequence of the protein of interest is
WO 2015/191270
PCT/US2015/032155 required in order to identify the protein of interest. Compared to other formats of multiplexing, mass spectrometry is unique in being able to exploit the full length of a protein's primary amino acid sequence to target unique identifier-type portions of a protein's primary amino acid sequence to virtually eliminate non-specific detection. In some embodiments of the present invention, a proteolytic fragment or set of proteolytic fragments that uniquely identifies a protein(s) of interest is used to detect the protein(s) of interest in a complex protein sample.
[0049] In some embodiments, disclosed methods enable the quantification or determination of ratios of multiple proteins in a complex protein sample by a single mass spectrometry analysis, as opposed to measuring each protein of interest individually multiple times and compiling the individual results into one sample result.
[0050] In some embodiments, the present disclosure also provides methods useful for the development and use of transgenic plant technology. Specifically, disclosed methods may be used to maintain the genotype of transgenic plants through successive generations. Also, some embodiments of the methods disclosed herein may be used to provide high-throughput analysis of non-transgenic plants that are at risk of being contaminated with transgenes from neighboring plants, for example, by cross-pollination. By these embodiments, bioconfinement of transgenes may be facilitated and/or accomplished. In other embodiments, methods disclosed herein may be used to screen the results of a plant transformation procedure in a high-throughput manner to identify transformants that exhibit desirable expression characteristics [0051] Any protein introduced into a plant via transgenic expression technology may be analyzed using methods of the invention. Proteins suitable for multiplex analysis according to the invention may confer an output trait that renders the transgenic plant superior to its nontransgenic counterpart. Non-limiting examples of desirable traits that may be conferred include herbicide resistance, resistance to insects, resistance to disease, resistance to environmental stress, enhanced yield, improved nutritional value, improved shelf life, altered oil content, altered oil composition, altered sugar content, altered starch content, production of plant-based pharmaceuticals, production of industrial products (for example polyhydroxyalkanoates: macromolecule polyesters considered ideal for replacing petroleumderived plastics), and potential for bioremediation. Moreover, the expression of one or more transgenic proteins within a single plant species may be analyzed using methods of the present disclosure. The addition or modulation of two or more genes or desired traits into a single species of interest is known as gene stacking. Furthermore, the expression of one or
WO 2015/191270
PCT/US2015/032155 more transgenic proteins may be analyzed concurrently in the presently disclosed multiplex analyses with one or more endogenous plant proteins.
[0052] Particularly suitable proteins that are expressed in transgenic plants are those that confer tolerance to herbicides for example the gene of 5'-enolpyruvyl-3'-phosphoshikimate synthase (EPSPS) or any variant thereof for conferring tolerance to glyphosate herbicides, the aryloxyalkanoate dioxygenase (AAD) for conferring tolerance to 2,4-D herbicides, the phosphinothricin acetyltransferase (PAT) for conferring tolerance to glufosinate herbicides, or combinations thereof.
[0053] The mass-to-charge ratio may be determined using a quadrupole analyzer. For example, in a “quadrupole” or “quadrupole ion trap” instrument, ions in an oscillating radio frequency field experience a force proportional to the DC potential applied between electrodes, the amplitude of the RF signal, and m/z. The voltage and amplitude can be selected so that only ions having a particular m/z travel the length of the quadrupole, while all other ions are deflected. Thus, quadrupole instruments can act as a “mass filter” and “mass detector” for the ions injected into the instrument.
[0054] Collision-induced dissociation (“CID”) is often used to generate the daughter ions for further detection. In CID, parent ions gain energy through collisions with an inert gas, such as argon, and subsequently fragmented by a process referred to as “unimolecular decomposition.” Sufficient energy must be deposited in the parent ion so that certain bonds within the ion can be broken due to increased energy.
[0055] The mass spectrometer typically provides the user with an ion scan; that is, the relative abundance of each m/z over a given range (for example 10 to 1200 amu). The results of an analyte assay, that is, a mass spectrum, can be related to the amount of the analyte in the original sample by numerous methods known in the art. For example, given that sampling and analysis parameters are carefully controlled, the relative abundance of a given ion can be compared to a table that converts that relative abundance to an absolute amount of the original molecule. Alternatively, molecular standards (e.g., internal standards and external standards) can be run with the samples and a standard curve constructed based on ions generated from those standards. Using such a standard curve, the relative abundance of a given ion can be converted into an absolute amount of the original molecule. Numerous other methods for relating the presence or amount of an ion to the presence or amount of the original molecule are well known to those of ordinary skill in the art.
[0056] The choice of ionization method can be determined based on the analyte to be measured, type of sample, the type of detector, the choice of positive versus negative mode,
WO 2015/191270
PCT/US2015/032155 etc. Ions can be produced using a variety of methods including, but not limited to, electron ionization, chemical ionization, fast atom bombardment, field desorption, and matrix-assisted laser desorption ionization (MALDI), surface enhanced laser desorption ionization (SELDI), desorption electrospray ionization (DESI), photon ionization, electrospray ionization, and inductively coupled plasma. Electrospray ionization refers to methods in which a solution is passed along a short length of capillary tube, to the end of which is applied a high positive or negative electric potential. Solution reaching the end of the tube, is vaporized (nebulized) into a jet or spray of very small droplets of solution in solvent vapor. This mist of droplets flows through an evaporation chamber which is heated to prevent condensation and to evaporate solvent. As the droplets get smaller the electrical surface charge density increases until such time that the natural repulsion between like charges causes ions as well as neutral molecules to be released.
[0057] The effluent of an LC may be injected directly and automatically (i.e., “in-line”) into the electrospray device. In some embodiments, proteins contained in an LC effluent are first ionized by electrospray into a parent ion.
[0058] Various different mass analyzers can be used in liquid chromatography - mass spectrometry combination (LC-MS). Exemplary mass analyzers include, but not limited to, single quadrupole, triple quadrupole, ion trap, TOF (time of flight), and quadrupole-time of flight (Q-TOF).
[0059] The quadrupole mass analyzer may consist of 4 circular rods, set parallel to each other. In a quadrupole mass spectrometer (QMS), the quadrupole is the component of the instrument responsible for filtering sample ions, based on their mass-to-charge ratio (m/z). Ions are separated in a quadrupole based on the stability of their trajectories in the oscillating electric fields that are applied to the rods.
[0060] An ion trap is a combination of electric or magnetic fields that captures ions in a region of a vacuum system or tube. Ion traps can be used in mass spectrometry while the ion’s quantum state is manipulated.
[0061] Time-of-flight mass spectrometry (TOFMS) is a method of mass spectrometry in which an ion’s mass-to-charge ratio is determined via a time measurement. Ions are accelerated by an electric field of known strength. This acceleration results in an ion having the same kinetic energy as any other ion that has the same charge. The velocity of the ion depends on the mass-to-charge ratio. The time that it subsequently takes for the particle to reach a detector at a known distance is measured. This time will depend on the mass-tocharge ratio of the particle (heavier particles reach lower speeds). From this time and the
WO 2015/191270
PCT/US2015/032155 known experimental parameters one can find the mass-to-charge ratio of the ion.
[0062] In some embodiments, the particular instrument used by the methods and/or systems provided may comprise a high fragmentation mode and a low fragmentation mode (or alternatively a non-fragmentation mode). Such different modes may include alternating scan high and low energy acquisition methodology to generate high resolution mass data. In some embodiments, the high resolution mass data may comprise a product data set (for example data derived from product ion (fragmented ions) under the high fragmentation mode) and a precursor data set (for example data derived from precursor ions (unfragmented ions) under the low fragmentation or non-fragmentation mode).
[0063] In some embodiments, the methods and/or systems provided use a mass spectrometer comprising a filtering device that may be used in the selection step, a fragmentation device that may be used in the fragmentation step, and/or one or more mass analyzers that may be used in the acquisition and/or mass spectrum creation step or steps. [0064] The filtering device and/or mass analyzer may comprise a quadrupole. The selection step and/or acquisition step and/or mass spectrum creation step or steps may involve the use of a resolving quadrupole. Additionally or alternatively, the filtering device may comprise a two dimensional or three dimensional ion trap or time-of-flight (ToF) mass analyzer. The mass analyzer or mass analyzers may comprise or further comprise one or more of a time-of-flight mass analyzer and/or an ion cyclotron resonance mass analyzer and/or an orbitrap mass analyzer and/or a two dimensional or three dimensional ion trap. [0065] Filtering by means of selection based upon mass-to-charge ratio (m/z) can be achieved by using a mass analyzer which can select ions based upon m/z, for example a quadrupole; or to transmit a wide m/z range, separate ions according to their m/z, and then select the ions of interest by means of their m/z value. An example of the latter would be a time-of-flight mass analyzer combined with a timed ion selector(s). The methods and/or systems provided may comprise isolating and/or separating the one or more proteins of interest, for example from two or more of a plurality of proteins, using a chromatographic technique for example liquid chromatography (LC). The method may further comprise measuring an elution time for the protein of interest and/or comparing the measured elution time with an expected elution time.
[0066] Additionally or alternatively, the proteins of interest may be separated using an ion mobility technique, which may be carried out using an ion mobility cell. Additionally, the proteins of interest may be selected by order or time of ion mobility drift. The method may further comprise measuring a drift time for the proteins of interest and/or comparing the
WO 2015/191270
PCT/US2015/032155 measured drift time with an expected drift time.
[0067] In some embodiments, the methods and/or systems provided are label-free, where quantitation can be achieved by comparison of the peak intensity, or area under the mass spectral peak for the precursor or product m/z values of interest between injections and across samples. In some embodiments, internal standard normalization may be used to account for any known associated analytical error. Another label-free method of quantification, spectral counting, involves summing the number of fragment ion spectra, or scans, that are acquired for each given peptide, in a non-redundant or redundant fashion. The associated peptide mass spectra for each protein are then summed, providing a measure of the number of scans per protein with this being proportional to its abundance. Comparison can then be made between samples/inj ections.
[0068] In some embodiments, the ion source is selected from the group consisting of: (1) an electrospray ionization (“ESI”) ion source; (2) an atmospheric pressure photo ionization (“APPI”) ion source; (3) an atmospheric pressure chemical ionization (“APCI”) ion source;
(4) a matrix assisted laser desorption ionization (“MALDI”) ion source; (5) a laser desorption ionization (“LDI”) ion source; (6) an atmospheric pressure ionization (“API”) ion source; (7) a desorption ionization on silicon (“DIOS”) ion source; (8) an electron impact (“El”) ion source; (9) a chemical ionization (“CI”) ion source; (10) a field ionization (“FI”) ion source; (11) a field desorption (“FD”) ion source; (12) an inductively coupled plasma (“ICP”) ion source; (13) a fast atom bombardment (“FAB”) ion source; (14) a liquid secondary ion mass spectrometry (“LSIMS”) ion source; (15) a desorption electrospray ionization (“DESI”) ion source; (16) a nickel- 63 radioactive ion source; (17) an atmospheric pressure matrix assisted laser desorption ionization ion source; and (18) a thermospray ion source.
[0069] In some embodiments, the methods and/or systems provided comprise an apparatus and/or control system configured to execute a computer program element comprising computer readable program code means for causing a processor to execute a procedure to implement the methods.
[0070] In some embodiments, the methods and/or systems provided use an alternating low and elevated energy scan function in combination with liquid chromatography separation of a plant extract. A list of information for proteins of interest can be provided including, but is not limited to, m/z of precursor ion, m/z of product ions, retention time, ion mobility drift time and rate of change of mobility. During the course of the LC separation and as the target ions elute into the mass spectrometer (and as either low energy precursor ions, or elevated energy product ions are detected, or the retention time window is activated) the mass analyzer
WO 2015/191270
PCT/US2015/032155 of the methods and/or systems provided may select a narrow m/z range (of a variable and changeable width) to pass ions through to the gas cell. Accordingly, the signal to noise ratio can be enhanced significantly for quantification of proteins of interest.
[0071] In some embodiments, at a chromatographic retention time when a targeted protein of interest is about to elute into the mass spectrometer ion source, the mass analyzer of the methods and/or systems provided can select a narrow m/z range (of a variable and changeable width) according to the targeted precursor ion. These selected ions are then transferred to an instrument stage capable of dissociating the ions by means of alternate and repeated switches between a high fragmentation mode where the sample precursor ions are substantially fragmented into product ions and a low fragmentation mode (or nonfragmentation mode) where the sample precursor ions are not substantially fragmented. Typically high resolution, accurate mass spectra are acquired in both modes and at the end of the experiment associated precursor and product ions are recognized by the closeness in fit of their chromatographic elution times and optionally other physicochemical properties. The signal intensity of either the precursor ion or the product ion associated with targeted proteins of interest can be used to determine the quantity of the proteins in the plant extract.
[0072] Those skilled in the art would understand certain variation can exist based on the disclosure provided. Thus, the following examples are given for the purpose of illustrating the invention and shall not be construed as being a limitation on the scope of the invention or claims.
EXAMPLES
Example 1 [0073] Plant samples (for example grain, leaf, root, forage, pollen) are extracted with assay buffer PBST combined with dithiothreitol (DTT). SEQ ID NO: 1 provides the protein sequence of 5-enolpyruvylshikimate-3-phosphate synthase (2mEPSPS):
MAGAEEIVLQPIKEISGTVKLPGSKSLSNRILLLAALSEGTTVVDNLLNSEDVHYMLG
ALRTLGLSVEADKAAKRAVVVGCGGKFPVEDAKEEVQLFLGNAGIAMRSLTAAVT
AAGGNATYVLDGVPRMRERPIGDLVVGLKQLGADVDCFLGTDCPPVRVNGIGGLPG
GKVKLSGSISSQYLSALLMAAPLALGDVEIEIIDKLISIPYVEMTLRLMERFGVKAEHS
DSWDRFYIKGGQKYKSPKNAYVEGDASSASYFLAGAAITGGTVTVEGCGTTSLQGD
VKFAEVLEMMGAKVTWTETSVTVTGPPREPFGRKHLKAIDVNMNKMPDVAMTLA
VVALF ADOPT AIRDVASWRVKETERMVAIRTELTKLGASVEEGPDYCIITPPEKLNVT
AIDTYDDHRMAMAFSLAACAEVPVTIRDPGCTRKTFPDYFDVLSTFVKN.
WO 2015/191270
PCT/US2015/032155
Table 1. Candidate signature peptides for 5-enolpyruvylshikimate-3-phosphate synthase (2mEPSPS)
SEQ ID NO 2 AGAEEIVLQPIK
SEQ ID NO 3 EISGTVK
SEQ ID NO 4 ILLLAALSEGTTVVDNLLNSEDVHYMKGALR
SEQ ID NO 5 TLGLSVEADK
SEQ ID NO 6 AVVVGCGGK
SEQ ID NO 7 FPVEDAK
SEQ ID NO 8 EEVQLFLGNAGIAMR
SEQ ID NO 9 SLTAAVTAAGGNATYVLDGVPR
SEQ ID NO 10 ERPIGDLVVGLK
SEQ ID NO 11 QLGADVDCFLGTDCPPVR
SEQ ID NO 12 VNGIGGLPGGK
SEQ ID NO 13 LSGSISSQYLSALLMAAPLALGDVEIEIIDK
SEQ ID NO 14 LISIPYVEMTLR
SEQ ID NO 15 AEHSDSWDR
SEQ ID NO 16 NAYVEGDASSASYFLAGAAITGGTVTVEGCGTTSLQGDVK
SEQ ID NO 17 FAEVLEMMGAK
SEQ ID NO 18 VTWTETSVTVTGPPR
SEQ ID NO 19 AIDVNMNK
SEQ ID NO 20 MPDVAMTLAVVALF ADOPT AIR
SEQ ID NO 21 DVASWR
SEQ ID NO 22 LGASVEEGPDYCIITPPEK
SEQ ID NO 23 LNVTAIDTYDDHR
SEQ ID NO 24 MAMAFSLAACAEVPVTIR
SEQ ID NO 25 TFPDYFDVLSTFVK
[0074] The extracted proteins are denatured and then proteolytically digested by adding trypsin protease and incubating at 37 °C for 15-20 hours. The digestion reactions are then acidified with formic acid (pH = 1-2) and are analyzed using LC-MS. The protein sequence for 2mEPSPS is analyzed and digested in silico to generate theoretical peptide fragments to be detected and measured by LC-MS. Candidate signature peptides for 5enolpyruvylshikimate-3-phosphate synthase (2mEPSPS) after trypsin digestion are listed in Table 1.
[0075] Surprisingly three candidate signature peptides provide good correlation for quantitation using LC-MS, as compared to results from Enzyme-Linked Immunosorbent Assay (ELISA) or other quantitation methods. These three signature peptides are EISGTVK
WO 2015/191270
PCT/US2015/032155 (SEQ ID NO: 3), DVASWR (SEQ ID NO: 21), and VNGIGGLPGGK (SEQ ID NO: 12). Both commercially synthesized peptides of these sequences as well as microbial-derived 2mEPSPS protein are used as analytical reference standards through the same digestion process as described above, where synthetic peptides can directly serve as an analytical reference standard for protein quantitation.
[0076] Representative data from HRAM LC-MS for Standard Chromatogram 500 ng/mL Synthetic Peptide are shown in FIG. 2, where comparison among total ion current (first panel from the top); combined extracted ion (second panel from the top); extracted ion 367.2082 m/z - EISGTVK (2+) (third panel from the top or the middle panel); extracted ion 367.1850 m/z - DVASWR (2+) (second panel from the bottom); and extracted ion 484.7798 m/z VNGIGGLPGGK (2+) (first panel from the bottom) can identify signature peak(s) for each signature peptide. Extracted window is 2.0 ppm for all ions.
[0077] Another representative data from HRAM LC-MS for Trypsin Digested Transgenic Soybean Sample Chromatogram are shown in FIG. 3, where comparison among total ion current (first panel from the top); combined extracted ion (second panel from the top); extracted ion 367.2082 m/z - EISGTVK (2+) (third panel from the top or the middle panel); extracted ion 367.1850 m/z - DVASWR (2+) (second panel from the bottom); and extracted ion 484.7798 m/z - VNGIGGLPGGK (2+) (first panel from the bottom) can also identify signature peak(s) for each signature peptide. Extracted window is 2.0 ppm for all ions.
[0078] Peak area of signature peak(s) for each signature peptide can be calculated and representative date of stacked HRAM LC-MS Standard (upper panel) and Transgenic (lower panel) Extracted Ion Chromatograms with peptide annotation are shown in FIG. 4 for quantitation. Extracted window is 2.0 ppm for all ions.
Example 2 [0079] Plant samples (for example grain, leaf, root, forage, pollen) are extracted with assay buffer PBST combined with dithiothreitol (DTT). The extracted proteins are denatured and then proteolytically digested by adding trypsin protease and incubating at 37 °C for 1520 hours. The digestion reactions are then acidified with formic acid (pH = 1-2) and are analyzed using LC-MS. SEQ ID NO: 26 provides the AAD-12 Protein Sequence: MAQTTLQITPTGATLGATVTGVHLATLDDAGFAALHAAWLQHALLIFPGQHLSNDQ QITFAKRFGAIERIGGGDIVAISNVKADGTVRQHSPAEWDDMMKVIVGNMAWHADS TYMPVMAQGAVFSAEVVPAVGGRTCFADMRAAYDALDEATRALVHQRSARHSLV YSQSKLGHVQQAGSAYIGYGMDTTATPLRPLVKVHPETGRPSLLIGRHAHAIPGMDA AESERFLEGLVDWACQAPRVHAHQWAAGDVVVWDNRCLLHRAEPWDFKLPRVM
WO 2015/191270
PCT/US2015/032155
WHSRLAGRPETEGAALV.
Table 2. Candidate signature peptides for aryloxyalkanoate dioxygenase-12 (AAD-12)
SEQ ID NO: 27 MAQTTLQITPTGATLLGATVTGVHLATLDDAGFAALHAAWL
QHALLIFPGQHLSNDQQITFAK
SEQ ID NO: 28 FGAIER
SEQ ID NO: 29 IGGGDIVAISNVK
SEQ ID NO: 30 ADGTVR
SEQ ID NO: 31 QHSPAEWDDMMK
SEQ ID NO: 32 VIVGNMAWHADSTYMPVMAQGAVFSAEVVPAVGGR
SEQ ID NO: 33 TCFADMR
SEQ ID NO: 34 AAYDALDEATR
SEQ ID NO: 35 ALVHQR
SEQ ID NO: 36 HSLVYSQSK
SEQ ID NO: 37 LQHVQQAGSAYIGYGMDTTATPLRPLVK
SEQ ID NO: 38 VHPETGRPSLLIGR
SEQ ID NO: 39 HAHAIPGMDAAESER
SEQ ID NO: 40 FLEGLVDWACQAPR
SEQ ID NO: 41 VHAHQWAAGDVVVWDNR
SEQ ID NO: 42 CLLHR
SEQ ID NO: 43 AEPWDFK
SEQ ID NO: 44 VMWHSR
SEQ ID NO: 45 LAGRPETEGAALV
[0080] The protein sequence for AAD-12 is analyzed and digested in silico to generate theoretical peptide fragments to be detected and measured by LC-MS. Candidate signature peptides for AAD-12 after trypsin digestion are listed in Table 2.
[0081] Surprisingly three candidate signature peptides provide good correlation for quantitation using LC-MS, as compared to results from Enzyme-Linked Immunosorbent Assay (ELISA) or other quantitation methods. These three signature peptides are FGAIER (SEQ ID NO: 28), IGGGDIVAISNVK (SEQ ID NO: 29), and AAYDALDEATR (SEQ ID NO: 34). Both commercially synthesized peptides of these sequences as well as microbialderived AAD-12 protein are used as analytical reference standards through the same digestion process as described above, where synthetic peptides can directly serve as an analytical reference standard for protein quantitation.
[0082] Representative data from HRAM LC-MS for Standard Chromatogram 500 ng/mL
WO 2015/191270
PCT/US2015/032155
Synthetic Peptide are shown in FIG. 5, where comparison among total ion current (first panel from the top); combined extracted ion (second panel from the top); extracted ion 346.6889 m/z - FGAIER (2+) (third panel from the top or the middle panel); extracted ion 621.8563 m/z - IGGGDIVAISNVK (2+) (second panel from the bottom); and extracted ion 598.2831 m/z - AAYDALDEATR (2+) (first panel from the bottom). Extracted window is 2.0 ppm for all ions.
[0083] Another representative data from HRAM LC-MS for Trypsin Digested Transgenic Soybean Sample Chromatogram are shown in FIG. 6, where comparison among total ion current (first panel from the top); combined extracted ion (second panel from the top); extracted ion 346.6889 m/z - FGAIER (2+) (third panel from the top or the middle panel); extracted ion 621.8563 m/z - IGGGDIVAISNVK (2+) (second panel from the bottom); and extracted ion 598.2831 m/z - AAYDALDEATR (2+) (first panel from the bottom) can also identify signature peak(s) for each signature peptide. Extracted window is 2.0 ppm for all ions.
[0084] Peak area of signature peak(s) for each signature peptide can be calculated and representative date of stacked HRAM LC-MS Standard (upper panel) and Transgenic (lower panel) Extracted Ion Chromatograms with peptide annotation are shown in FIG. 7 for quantitation. Extracted window is 2.0 ppm for all ions.
Example 3 [0085] Plant samples (for example grain, leaf, root, forage, pollen) are extracted with assay buffer PBST combined with dithiothreitol (DTT). The extracted proteins are denatured and then proteolytically digested by adding trypsin protease and incubating at 37 °C for 1520 hours. The digestion reactions are then acidified with formic acid (pH = 1-2) and are analyzed using LC-MS. SEQ ID NO: 46 provides the protein sequence of phosphinothricin acetyltransferase (PAT):
MSPERRPVEIRPATAADMAAVCDIVNHYIETSTVNFRTEPQTPQEWIDDLERLQDRYP
WLVAEVEGVVAGIAYAGPWKARNAYDWTVESTVYVSHRHQRLGLGSTLYTHLLKS
MEAQGFKSVVAVIGLPNDPSVRLHEALGYTARGTLRAAGYKHGGWHDVGFWQRD
FELPAPPRPVRPVTQI.
[0086] The protein sequence for PAT is analyzed and digested in silico to generate theoretical peptide fragments to be detected and measured by LC-MS. Candidate signature peptides for phosphinothricin acetyltransferase (PAT) after trypsin digestion are listed in Table 3.
WO 2015/191270
PCT/US2015/032155
Table 3. Candidate signature peptides for phosphinothricin acetyltransferase (PAT)
SEQ ID NO: 47 MSPER
SEQ ID NO: 48 RPVEIRPATAADMAAVCDIVNHYIETSTVNFR
SEQ ID NO: 49 TEPQTPQEWIDDLER
SEQ ID NO: 50 LQDR
SEQ ID NO: 51 YPWLVAEVEGVVAGIAYAGPWK
SEQ ID NO: 52 NAYDWTVESTVYVSHR
SEQ ID NO: 53 LGLGSTLYTHLLK
SEQ ID NO: 54 SMEAQGFK
SEQ ID NO: 55 SVVAVIGLPNDPSVR
SEQ ID NO: 56 LHEALGYTAR
SEQ ID NO: 57 GTLR
SEQ ID NO: 58 AAGYK
SEQ ID NO: 59 HGGWHDVGFWQR
SEQ ID NO: 60 DFELPAPPRPVRPVTQI
[0087] Surprisingly three candidate signature peptides provide good correlation for quantitation using LC-MS, as compared to results from Enzyme-Linked Immunosorbent Assay (ELISA) or other quantitation methods. These three signature peptides are TEPQTPQEWIDDLER (SEQ ID NO: 49), SVVAVIGLPNDPSVR (SEQ ID NO: 55), and LHEALGYTAR (SEQ ID NO: 56). Both commercially synthesized peptides of these sequences as well as microbial-derived PAT protein are used as analytical reference standards through the same digestion process as described above, where synthetic peptides can directly serve as an analytical reference standard for protein quantitation.
[0088] Representative data from HRAM LC-MS for Standard Chromatogram 500 ng/mL Synthetic Peptide are shown in FIG. 8, where comparison among total ion current (first panel from the top); combined extracted ion (second panel from the top); extracted ion 928.9367 m/z - TEPQTPQEWIDDLER (2+) (third panel from the top or the middle panel); extracted ion 761.9330 m/z - SVVAVIGLPNDPSVR (2+) (second panel from the bottom); and extracted ion 565.8013 m/z - LHEALGYTAR (2+) (first panel from the bottom) can identify signature peak(s) for each signature peptide. Extracted window is 2.0 ppm for all ions.
[0089] Another representative data from HRAM LC-MS for Trypsin Digested Transgenic Soybean Sample Chromatogram are shown in FIG. 9, where comparison among total ion current (first panel from the top); combined extracted ion (second panel from the top); extracted ion 928.9367 m/z - TEPQTPQEWIDDLER (2+) (third panel from the top or the
WO 2015/191270
PCT/US2015/032155 middle panel); extracted ion 761.9330 m/z - SVVAVIGLPNDPSVR (2+) (second panel from the bottom); and extracted ion 565.8013 m/z - LHEALGYTAR (2+) (first panel from the bottom) can also identify signature peak(s) for each signature peptide. Extracted window is 2.0 ppm for all ions.
[0090] Peak area of signature peak(s) for each signature peptide can be calculated and representative date of stacked E1RAM LC-MS Standard (upper panel) and Transgenic (lower panel) Extracted Ion Chromatograms with peptide annotation are shown in FIG. 10 for quantitation. Extracted window is 2.0 ppm for all ions.
1002054750
2015275086 18 Jan 2018

Claims (16)

  1. We claim:
    1. A high-throughput method of quantitating one or more protein(s) of interest with known amino acid sequence in a plant-based sample, the method comprising:
    (a) extracting proteins from a plant-based sample;
    (b) digesting proteins extracted from step (a) to obtain peptides;
    (c) separating the peptides in a single step;
    (d) determining a plurality of signature peptides from the protein of interest with known amino acid sequence, wherein the plurality of signature peptides comprises SEQ ID NOs:28, 29 and 34;
    (e) measuring the plurality of signature peptides using high resolution accurate mass spectrometry (HRAM MS); and (f) quantitating the protein of interest with known amino acid sequence based on measurements of the signature peptides.
  2. 2. The method of claim 1, wherein the peptides are separated in a single step by column chromatography.
  3. 3. The method of claim 2, wherein the column chromatography comprises a liquid column chromatography.
  4. 4. The method of any one of claims 1 to 3, wherein mass spectral data for the peptides corresponding to the protein(s) of interest are obtained in a single step.
  5. 5. The method of any one of claims 1 to 4, wherein the one or more protein(s) of interest comprises two proteins of interest.
  6. 6. The method of any one of claims 1 to 4, wherein the one or more protein(s) of interest comprises four proteins of interest.
  7. 7. The method of any one of claims 1 to 6, wherein the plant-based sample is from a transgenic plant.
    1002093940
    2015275086 27 Feb 2018
  8. 8. The method of claim 7, wherein the one or more protein(s) of interest comprises expected product of transgene expression in the transgenic plant.
  9. 9. The method of any one of claims 1 to 8, wherein the one or more protein(s) of interest further comprises 5-enolpyruvylshikimate-3-phosphate synthase (2mEPSPS), and phosphinothricin acetyltransferase (PAT).
  10. 10. The method of any one of claims 1 to 9, wherein the plurality of signature peptides further comprises at least one sequence selected from the group consisting of SEQ ID NOs: 2-25, and 47-60.
  11. 11. The method of any one of claims 1 to 9, wherein the plurality of signature peptides further comprises at least two sequences selected from the group consisting of SEQ ID NOs: 2-25, and 47-60.
  12. 12. The method of any one of claims 1 to 9, wherein the plurality of signature peptides further comprises at least three sequences selected from the group consisting of SEQ ID NOs: 2-25, and 47-60.
  13. 13. The method of any one of claims 1 to 9, wherein the plurality of signature peptides further comprises (1) SEQ ID NOs 3, 12, and 21; and (2) SEQ IN NOs: 49, 55, and 56.
  14. 14. The method of any one of claims 1 to 13, wherein measuring the plurality of signature peptides comprises calculating corresponding peak heights or peak areas.
  15. 15. The method of any one of claims 1 to 13, wherein measuring the plurality of signature peptides comprises comparing data from high fragmentation mode and low fragmentation mode.
    WO 2015/191270
    PCT/US2015/032155
    1/10
    Protein Mixture
    Protease
    Digestion
    MS
    Maize Tissue \
    © Calibiationstandaids A Unknown samples
    1. Extract ion chromatograms
    2. Quantify peak areas
    3. Reference standard curves
    4. Calculate protein levels
    FIG. 1
    Peptide Mixture
    WO 2015/191270
    PCT/US2015/032155
    2/10
    RT: 0.00-7.51 SM: 7B 100n
    4-69 4.98 5.25 5,50 5.74
    100q
    3.33
    6.90
    500 | ΓΓΪϊρΊΊ’Γ'Ι'Ί'ΎΤΪ μΊ'Τ'ί''|ΤΪΪΤ'|'’ΪΊ'Ί'Τ’|''ΪΊΊ R ’ I ”Γ ’ Ί” Ί” r ’ I ”Γ ’ Ί” Ί” Ί” i ” Γ ”Γ ’ Ί” Ί” i ” Γ ”Γ ’ Ί” Ί” I ” Γ ”f ’ Ί” Ί” I ” Γ'
    0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0
    Time (min)
    6.5
    7.0
    FIG. 2
    WO 2015/191270
    PCT/US2015/032155
    3/10
    FIG. 3
    WO 2015/191270
    PCT/US2015/032155
    4/10
    Relative Abundance Relative Abundance
    EISGTVK DVASWR VNGIGGLPGGK
    FIG. 4
    WO 2015/191270
    PCT/US2015/032155
    5/10
    500J ιοθη
    50:
    0:
    3.32
    0.0 0.5 1.0 1.5 2.0 2.5
    3.0
    3.5 4.0
    Time (min)
    4.5 5.0 5.5 6.0 6.5 7.0
    FIG. 5
    WO 2015/191270
    PCT/US2015/032155
    6/10
    503.29
    1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0
    Time (min) θ ρ*ττττ*Π“ττη“
    0.0 0.5 1.0
    6.05 622 6.23 '|πϊΤ| η Γϊϊττπϊτ·
    5.5 6.0 6.5 7.0
    FIG. 6
    WO 2015/191270
    PCT/US2015/032155
    7/10
    Relative Abundance Relative Abundance
    FIG. 7
    WO 2015/191270
    PCT/US2015/032155
    8/10
    RT: 0.00-7.51 SM: 7B
    5.87
    100500:
    1005002.46
    0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0
    Time (min)
    FIG. 8
    WO 2015/191270
    PCT/US2015/032155
    9/10
    RT: 0.00 - 7.51 SM: 7B
    0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0
    Time (min)
    FIG. 9
    WO 2015/191270
    PCT/US2015/032155
    10/10
    Relative Abundance Relative Abundance
    TEPQTPQEWIDDLER
    FIG. 10
    75620-WO-PCT-20150520-Sequence-Listing-ST25.txt SEQUENCE LISTING <110> Dow AgroSciences LLC Oman, Trent J.
    Hill, Ryan C.
    Schafer, Barry W.
    Gilbert, Jeffrey R.
    Shan, Guomin <120> QUANTITATIVE ANALYSIS OF TRANSGENIC PROTEINS <130> 75620 <160> 60 <170> PatentIn version 3.5 <210> 1 <211> 445 <212> PRT <213> Arabidopsis thaliana <400> 1
    Met 1 Ala Gly Ala Glu 5 Glu Ile Val Leu Gln 10 Pro Ile Lys Glu Ile 15 Ser Gly Thr Val Lys Leu Pro Gly Ser Lys Ser Leu Ser Asn Arg Ile Leu 20 25 30 Leu Leu Ala Ala Leu Ser Glu Gly Thr Thr Val Val Asp Asn Leu Leu 35 40 45 Asn Ser Glu Asp Val His Tyr Met Leu Gly Ala Leu Arg Thr Leu Gly 50 55 60 Leu Ser Val Glu Ala Asp Lys Ala Ala Lys Arg Ala Val Val Val Gly 65 70 75 80 Cys Gly Gly Lys Phe Pro Val Glu Asp Ala Lys Glu Glu Val Gln Leu 85 90 95 Phe Leu Gly Asn Ala Gly Ile Ala Met Arg Ser Leu Thr Ala Ala Val 100 105 110 Thr Ala Ala Gly Gly Asn Ala Thr Tyr Val Leu Asp Gly Val Pro Arg 115 120 125 Met Arg Glu Arg Pro Ile Gly Asp Leu Val Val Gly Leu Lys Gln Leu 130 135 140 Gly Ala Asp Val Asp Cys Phe Leu Gly Thr Asp Cys Pro Pro Val Arg 145 150 155 160 Val Asn Gly Ile Gly Gly Leu Pro Gly Gly Lys Val Lys Leu Ser Gly 165 170 175
    Page 1
    75620-WO-PCT-20150520-Sequence-Listing-ST25.txt Ser Ile Ser Ser Gln Tyr Leu Ser Ala Leu Leu Met Ala Ala Pro Leu
    180 185 190
    Ala Leu Gly Asp Val Glu Ile Glu Ile 200 Ile Asp Lys Leu 205 Ile Ser Ile 195 Pro Tyr Val Glu Met Thr Leu Arg Leu Met Glu Arg Phe Gly Val Lys 210 215 220 Ala Glu His Ser Asp Ser Trp Asp Arg Phe Tyr Ile Lys Gly Gly Gln 225 230 235 240 Lys Tyr Lys Ser Pro Lys Asn Ala Tyr Val Glu Gly Asp Ala Ser Ser 245 250 255 Ala Ser Tyr Phe Leu Ala Gly Ala Ala Ile Thr Gly Gly Thr Val Thr 260 265 270 Val Glu Gly Cys Gly Thr Thr Ser Leu Gln Gly Asp Val Lys Phe Ala 275 280 285 Glu Val Leu Glu Met Met Gly Ala Lys Val Thr Trp Thr Glu Thr Ser 290 295 300 Val Thr Val Thr Gly Pro Pro Arg Glu Pro Phe Gly Arg Lys His Leu 305 310 315 320 Lys Ala Ile Asp Val Asn Met Asn Lys Met Pro Asp Val Ala Met Thr 325 330 335 Leu Ala Val Val Ala Leu Phe Ala Asp Gly Pro Thr Ala Ile Arg Asp 340 345 350 Val Ala Ser Trp Arg Val Lys Glu Thr Glu Arg Met Val Ala Ile Arg 355 360 365 Thr Glu Leu Thr Lys Leu Gly Ala Ser Val Glu Glu Gly Pro Asp Tyr 370 375 380 Cys Ile Ile Thr Pro Pro Glu Lys Leu Asn Val Thr Ala Ile Asp Thr 385 390 395 400 Tyr Asp Asp His Arg Met Ala Met Ala Phe Ser Leu Ala Ala Cys Ala 405 410 415 Glu Val Pro Val Thr Ile Arg Asp Pro Gly Cys Thr Arg Lys Thr Phe 420 425 430 Pro Asp Tyr Phe Asp Val Leu Ser Thr Phe Val Lys Asn 435 440 445
    Page 2
    75620-WO-PCT-20150520-Sequence-Listing-ST25.txt
    <210> 2 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Candidate signature peptide <400> 2 Ala Gly Ala Glu Glu Ile Val Leu Gln Pro Ile Lys 1 5 10 <210> 3 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Candidate signature peptide
    <400> 3
    Glu Ile Ser Gly Thr Val Lys 1 5 <210> 4 <211> 31 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 4
    Ile Leu Leu Leu Ala Ala Leu Ser Glu Gly Thr Thr Val Val Asp Asn 1 5 10 15 Leu Leu Asn Ser Glu Asp Val His Tyr Met Lys Gly Ala Leu Arg
  16. 20 25 30 <210> 5 <211> 10 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 5
    Thr Leu Gly Leu Ser Val Glu Ala Asp Lys
    1 5 <210> 6 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Candidate signature peptide
    Page 3
    75620-WO-PCT-20150520-Sequence-Listing-ST25.txt <400> 6
    Ala Val Val Val Gly Cys Gly Gly Lys 1 5 <210> 7 <211> 7 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 7
    Phe Pro Val Glu Asp Ala Lys 1 5 <210> 8 <211> 15 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 8
    Glu Glu Val Gln Leu Phe Leu Gly Asn Ala Gly Ile Ala Met Arg 1 5 10 15 <210> 9 <211> 22 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 9
    Ser Leu Thr Ala Ala Val Thr Ala Ala Gly Gly Asn Ala Thr Tyr Val 1 5 10 15
    Leu Asp Gly Val Pro Arg 20 <210> 10 <211> 12 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 10
    Glu Arg Pro Ile Gly Asp Leu Val Val Gly Leu Lys 1 5 10 <210> 11 <211> 18
    Page 4
    75620-WO-PCT-20150520-Sequence-Listing-ST25.txt <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 11
    Gln Leu Gly Ala Asp Val Asp Cys Phe Leu Gly Thr Asp Cys Pro Pro 1 5 10 15
    Val Arg <210> 12 <211> 11 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 12
    Val Asn Gly Ile Gly Gly Leu Pro Gly Gly Lys 1 5 10 <210> 13 <211> 31 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 13
    Leu Ser Gly Ser Ile Ser Ser Gln Tyr Leu Ser Ala Leu Leu Met Ala 1 5 10 15 Ala Pro Leu Ala Leu Gly Asp Val Glu Ile Glu Ile Ile Asp Lys
    20 25 30 <210> 14 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Candidate signature peptide <400> 14 Leu Ile Ser Ile Pro Tyr Val Glu Met Thr Leu Arg 1 5 10 <210> 15 <211> 9 <212> PRT <213> Artificial Sequence
    <220>
    Page 5
    75620-WO-PCT-20150520-Sequence-Listing-ST25.txt <223> Candidate signature peptide
    <400> 15 Ala Glu His Ser Asp Ser Trp Asp Arg 1 5 <210> 16 <211> 40 <212> PRT <213> Artificial Sequence <220> <223> Candidate signature peptide
    <400> 16
    Asn Ala Tyr 1 Val Glu Gly 5 Asp Ala Ser Ser 10 Ala Ser Tyr Phe Leu 15 Ala Gly Ala Ala Ile Thr Gly Gly Thr Val Thr Val Glu Gly Cys Gly Thr 20 25 30 Thr Ser Leu Gln Gly Asp Val Lys
    35 40 <210> 17 <211> 11 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 17
    Phe Ala Glu Val Leu Glu Met Met Gly Ala Lys
    1 5 10 <210> 18 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Candidate signature peptide <400> 18 Val Thr Trp Thr Glu Thr Ser Val Thr Val Thr Gly Pro Pro Arg 1 5 10 15 <210> 19 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Candidate signature peptide <400> 19
    Page 6
    75620-WO-PCT-20150520-Sequence-Listing-ST25.txt Ala Ile Asp Val Asn Met Asn Lys 1 5 <210> 20 <211> 22 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 20
    Met Pro Asp Val Ala Met Thr Leu Ala Val Val Ala Leu Phe Ala Asp 1 5 10 15
    Gly Pro Thr Ala Ile Arg 20 <210> 21 <211> 6 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 21
    Asp Val Ala Ser Trp Arg
    1 5 <210> 22 <211> 19 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 22
    Leu Gly Ala Ser Val Glu Glu Gly Pro Asp Tyr Cys Ile Ile Thr Pro 1 5 10 15
    Pro Glu Lys <210> 23 <211> 13 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 23
    Leu Asn Val Thr Ala Ile Asp Thr Tyr Asp Asp His Arg 1 5 10
    Page 7
    75620-WO-PCT-20150520-Sequence-Listing-ST25.txt <210> 24 <211> 18 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 24
    Met Ala Met Ala Phe Ser Leu Ala Ala Cys Ala Glu Val Pro Val Thr 1 5 10 15
    Ile Arg <210> 25 <211> 14 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 25
    Thr Phe Pro Asp Tyr Phe Asp Val Leu Ser Thr Phe Val Lys 1 5 10 <210> 26 <211> 293 <212> PRT <213> Delftia acidovorans
    <400> 26 Met Ala Gln Thr Thr Leu Gln Ile Thr Pro Thr Gly Ala Thr Leu Gly 1 5 10 15 Ala Thr Val Thr Gly Val His Leu Ala Thr Leu Asp Asp Ala Gly Phe 20 25 30 Ala Ala Leu His Ala Ala Trp Leu Gln His Ala Leu Leu Ile Phe Pro 35 40 45 Gly Gln His Leu Ser Asn Asp Gln Gln Ile Thr Phe Ala Lys Arg Phe 50 55 60 Gly Ala Ile Glu Arg Ile Gly Gly Gly Asp Ile Val Ala Ile Ser Asn 65 70 75 80 Val Lys Ala Asp Gly Thr Val Arg Gln His Ser Pro Ala Glu Trp Asp 85 90 95 Asp Met Met Lys Val Ile Val Gly Asn Met Ala Trp His Ala Asp Ser 100 105 110 Thr Tyr Met Pro Val Met Ala Gln Gly Ala Val Phe Ser Ala Glu Val
    Page 8
    115 75620-WO-PCT-20150520-Sequence- 120 Listing-ST25.txt 125 Val Pro Ala Val Gly Gly Arg Thr Cys Phe Ala Asp Met Arg Ala Ala 130 135 140 Tyr Asp Ala Leu Asp Glu Ala Thr Arg Ala Leu Val His Gln Arg Ser 145 150 155 160 Ala Arg His Ser Leu Val Tyr Ser Gln Ser Lys Leu Gly His Val Gln 165 170 175 Gln Ala Gly Ser Ala Tyr Ile Gly Tyr Gly Met Asp Thr Thr Ala Thr 180 185 190 Pro Leu Arg Pro Leu Val Lys Val His Pro Glu Thr Gly Arg Pro Ser 195 200 205 Leu Leu Ile Gly Arg His Ala His Ala Ile Pro Gly Met Asp Ala Ala 210 215 220 Glu Ser Glu Arg Phe Leu Glu Gly Leu Val Asp Trp Ala Cys Gln Ala 225 230 235 240 Pro Arg Val His Ala His Gln Trp Ala Ala Gly Asp Val Val Val Trp 245 250 255 Asp Asn Arg Cys Leu Leu His Arg Ala Glu Pro Trp Asp Phe Lys Leu 260 265 270 Pro Arg Val Met Trp His Ser Arg Leu Ala Gly Arg Pro Glu Thr Glu 275 280 285
    Gly Ala Ala Leu Val 290 <210> 27 <211> 63 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 27
    Met Ala Gln Thr Thr Leu Gln Ile Thr Pro Thr Gly Ala Thr Leu Leu 1 5 10 15 Gly Ala Thr Val Thr Gly Val His Leu Ala Thr Leu Asp Asp Ala Gly 20 25 30 Phe Ala Ala Leu His Ala Ala Trp Leu Gln His Ala Leu Leu Ile Phe
    35 40 45
    Page 9
    75620-WO-PCT-20150520-Sequence-Listing-ST25.txt
    Pro Gly Gln His Leu Ser Asn Asp Gln Gln Ile Thr Phe Ala Lys 50 55 60 <210> 28 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Candidate signature peptide
    <400> 28
    Phe Gly Ala Ile Glu Arg
    1 5 <210> 29 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> Candidate signature peptide <400> 29 Ile Gly Gly Gly Asp Ile Val Ala Ile Ser Asn Val Lys 1 5 10 <210> 30 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Candidate signature peptide <400> 30 Ala Asp Gly Thr Val Arg 1 5
    <210> 31 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Candidate signature peptide <400> 31 Gln His Ser Pro Ala Glu Trp Asp Asp Met Met Lys 1 5 10 <210> 32 <211> 35 <212> PRT <213> Artificial Sequence <220> <223> Candidate signature peptide
    Page 10
    75620-WO-PCT-20150520-Sequence-Listing-ST25.txt <400> 32
    Val 1 Ile Val Gly Asn 5 Met Ala Trp His Ala 10 Asp Ser Thr Tyr Met 15 Pro Val Met Ala Gln Gly Ala Val Phe Ser Ala Glu Val Val Pro Ala Val 20 25 30
    Gly Gly Arg 35 <210> 33 <211> 7 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 33
    Thr Cys Phe Ala Asp Met Arg 1 5 <210> 34 <211> 11 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 34
    Ala Ala Tyr Asp Ala Leu Asp Glu Ala Thr Arg 1 5 10 <210> 35 <211> 6 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 35
    Ala Leu Val His Gln Arg
    1 5 <210> 36 <211> 9 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 36
    His Ser Leu Val Tyr Ser Gln Ser Lys
    Page 11
    75620-WO-PCT-20150520-Sequence-Listing-ST25.txt <210> 37 <211> 28 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide
    <400> Leu Gln 1 37 Tyr Ile Gly Tyr Gly Met 15 His Val Gln Gln Ala 5 Gly Ser Ala 10 Asp Thr Thr Ala Thr Pro Leu Arg Pro Leu Val Lys 20 25 <210> 38 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Candidate signature peptide <400> 38 Val His ; Pro Glu Thr Gly Arg Pro Ser Leu Leu Ile Gly Arg 1 5 10 <210> 39 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Candidate signature peptide <400> 39 His Ala His Ala Ile Pro Gly Met Asp Ala Ala Glu Ser Glu Arg 1 5 10 15 <210> 40 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Candidate signature peptide <400> 40 Phe Leu Glu Gly Leu Val Asp Trp Ala Cys Gln Ala Pro Arg
    1 5 10 <210> 41 <211> 17 <212> PRT <213> Artificial Sequence
    Page 12
    75620-WO-PCT-20150520-Sequence-Listing-ST25.txt <220>
    <223> Candidate signature peptide <400> 41
    Val His Ala His Gln Trp Ala Ala Gly Asp Val Val Val Trp Asp Asn 1 5 10 15
    Arg <210> 42 <211> 5 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 42
    Cys Leu Leu His Arg
    1 5 <210> 43 <211> 7 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 43
    Ala Glu Pro Trp Asp Phe Lys 1 5 <210> 44 <211> 6 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 44
    Val Met Trp His Ser Arg
    1 5 <210> 45 <211> 13 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 45
    Leu Ala Gly Arg Pro Glu Thr Glu Gly Ala Ala Leu Val 1 5 10
    Page 13
    75620-WO-PCT-20150520-Sequence-Listing-ST25.txt <210> 46 <211> 183 <212> PRT <213> Streptomyces viridochromogenes <400> 46
    Met 1 Ser Pro Glu Arg Arg Pro Val 5 Glu Ile 10 Arg Pro Ala Thr Ala 15 Ala Asp Met Ala Ala Val Cys Asp Ile Val Asn His Tyr Ile Glu Thr Ser 20 25 30 Thr Val Asn Phe Arg Thr Glu Pro Gln Thr Pro Gln Glu Trp Ile Asp 35 40 45 Asp Leu Glu Arg Leu Gln Asp Arg Tyr Pro Trp Leu Val Ala Glu Val 50 55 60 Glu Gly Val Val Ala Gly Ile Ala Tyr Ala Gly Pro Trp Lys Ala Arg 65 70 75 80 Asn Ala Tyr Asp Trp Thr Val Glu Ser Thr Val Tyr Val Ser His Arg 85 90 95 His Gln Arg Leu Gly Leu Gly Ser Thr Leu Tyr Thr His Leu Leu Lys 100 105 110 Ser Met Glu Ala Gln Gly Phe Lys Ser Val Val Ala Val Ile Gly Leu 115 120 125 Pro Asn Asp Pro Ser Val Arg Leu His Glu Ala Leu Gly Tyr Thr Ala 130 135 140 Arg Gly Thr Leu Arg Ala Ala Gly Tyr Lys His Gly Gly Trp His Asp 145 150 155 160 Val Gly Phe Trp Gln Arg Asp Phe Glu Leu Pro Ala Pro Pro Arg Pro 165 170 175 Val Arg Pro Val Thr Gln Ile
    180 <210> 47 <211> 5 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 47
    Met Ser Pro Glu Arg
    1 5
    Page 14
    75620-WO-PCT-20150520-Sequence-Listing-ST25.txt
    <210> 48 <211> 32 <212> PRT <213> Artificial Sequence <220> <223> Candidate signature peptide
    <400> 48
    Arg Pro Val Glu Ile Arg Pro Ala Thr Ala Ala Asp Met Ala Ala Val 1 5 10 15 Cys Asp Ile Val Asn His Tyr Ile Glu Thr Ser Thr Val Asn Phe Arg
    20 25 30 <210> 49 <211> 15 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 49
    Thr Glu Pro Gln Thr Pro Gln Glu Trp Ile Asp Asp Leu Glu Arg 1 5 10 15 <210> 50 <211> 4 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 50
    Leu Gln Asp Arg <210> 51 <211> 22 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 51
    Tyr Pro Trp Leu Val Ala Glu Val Glu Gly Val Val Ala Gly Ile Ala 1 5 10 15
    Tyr Ala Gly Pro Trp Lys 20 <210> 52 <211> 16
    Page 15
    75620-WO-PCT-20150520-Sequence-Listing-ST25.txt <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 52
    Asn Ala Tyr Asp Trp Thr Val Glu Ser Thr 10 Val Tyr Val Ser His Arg 15 1 5 <210> 53 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> Candidate signature peptide <400> 53 Leu Gly Leu Gly Ser Thr Leu Tyr Thr His Leu Leu Lys 1 5 10
    <210> 54 <211> 8 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 54
    Ser Met Glu Ala Gln Gly Phe Lys 1 5 <210> 55 <211> 15 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 55
    Ser Val Val Ala Val Ile Gly Leu Pro Asn Asp Pro Ser Val Arg 1 5 10 15 <210> 56 <211> 10 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 56
    Leu His Glu Ala Leu Gly Tyr Thr Ala Arg 1 5 10
    Page 16
    75620-WO-PCT-20150520-Sequence-Listing-ST25.txt <210> 57 <211> 4 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 57
    Gly Thr Leu Arg <210> 58 <211> 5 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 58
    Ala Ala Gly Tyr Lys
    1 5 <210> 59 <211> 12 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 59
    His Gly Gly Trp His Asp Val Gly Phe Trp Gln Arg 1 5 10 <210> 60 <211> 17 <212> PRT <213> Artificial Sequence <220>
    <223> Candidate signature peptide <400> 60
    Asp Phe Glu Leu Pro Ala Pro Pro Arg Pro Val Arg Pro Val Thr Gln 1 5 10 15
    Ile
    Page 17
AU2015275086A 2014-06-10 2015-05-22 Quantitative analysis of transgenic proteins Ceased AU2015275086B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462010137P 2014-06-10 2014-06-10
US201462010113P 2014-06-10 2014-06-10
US201462010126P 2014-06-10 2014-06-10
US62/010,113 2014-06-10
US62/010,137 2014-06-10
US62/010,126 2014-06-10
PCT/US2015/032155 WO2015191270A1 (en) 2014-06-10 2015-05-22 Quantitative analysis of transgenic proteins

Publications (2)

Publication Number Publication Date
AU2015275086A1 AU2015275086A1 (en) 2016-12-08
AU2015275086B2 true AU2015275086B2 (en) 2018-03-15

Family

ID=53366296

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015275086A Ceased AU2015275086B2 (en) 2014-06-10 2015-05-22 Quantitative analysis of transgenic proteins

Country Status (14)

Country Link
US (2) US20150355189A1 (en)
EP (1) EP3155432A1 (en)
JP (1) JP2017519206A (en)
KR (1) KR20170010381A (en)
CN (1) CN106461610A (en)
AU (1) AU2015275086B2 (en)
BR (1) BR112016028496A2 (en)
CA (1) CA2951250A1 (en)
CL (1) CL2016003146A1 (en)
IL (1) IL249395A0 (en)
MX (1) MX2016016054A (en)
RU (1) RU2016148876A (en)
TW (1) TW201625943A (en)
WO (1) WO2015191270A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2958074A1 (en) * 2014-08-11 2016-02-18 Dow Agrosciences Llc Systems and methods for selective quantitation and detection of allergens
BR112017002622A2 (en) * 2014-08-11 2018-02-20 Dow Agrosciences Llc methods and systems for selective quantification and allergen detection
WO2018140370A1 (en) * 2017-01-25 2018-08-02 Dow Agrosciences Llc Methods and systems for selective quantitation and detection of allergens including gly m 7
US20180284108A1 (en) * 2017-04-01 2018-10-04 Michael Joseph Pugia Method for complete and fragmented markers
CN108593727B (en) * 2018-04-28 2020-03-24 山东农业大学 Photoelectrochemical sensor for detecting histone acetyltransferase and detection method thereof
US20210190794A1 (en) * 2018-08-27 2021-06-24 Syngenta Participations Ag Compositions and methods for protein detection
WO2020202861A1 (en) * 2019-04-03 2020-10-08 株式会社島津製作所 Analysis method, microbe identifying method and testing method
AU2020266482A1 (en) * 2019-04-29 2021-10-07 Syngenta Crop Protection Ag Compositions and methods for protein detection
CN111111255B (en) * 2019-11-14 2021-09-17 南开大学 Method for extracting amino acid from soybean phloem
CN112946056A (en) * 2021-01-29 2021-06-11 山东省食品药品检验研究院 Method for detecting aluminum element in alanyl glutamine injection
CN114280306B (en) * 2021-05-27 2023-05-05 中国农业科学院植物保护研究所 ELISA detection kit and detection method for eleusine indica EPSPS protein

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050153380A1 (en) * 2001-04-17 2005-07-14 Ista Spa Methods for mass spectrometry detection and quantification of specific target proteins in complex biological samples
WO2007132164A2 (en) * 2006-05-02 2007-11-22 Royal Holloway And Bedford New College Analysis of proteins
WO2010141674A2 (en) * 2009-06-03 2010-12-09 Dow Agrosciences Llc Multiplex analysis of stacked transgenic protein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050153380A1 (en) * 2001-04-17 2005-07-14 Ista Spa Methods for mass spectrometry detection and quantification of specific target proteins in complex biological samples
WO2007132164A2 (en) * 2006-05-02 2007-11-22 Royal Holloway And Bedford New College Analysis of proteins
WO2010141674A2 (en) * 2009-06-03 2010-12-09 Dow Agrosciences Llc Multiplex analysis of stacked transgenic protein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ULLA SEPPÄLÄ ET AL, JOURNAL OF PROTEOME RESEARCH, (20110401), vol. 10, no. 4, pages 2113 - 2122 *

Also Published As

Publication number Publication date
WO2015191270A1 (en) 2015-12-17
JP2017519206A (en) 2017-07-13
AU2015275086A1 (en) 2016-12-08
EP3155432A1 (en) 2017-04-19
BR112016028496A2 (en) 2017-10-24
IL249395A0 (en) 2017-02-28
CL2016003146A1 (en) 2017-06-02
MX2016016054A (en) 2017-07-13
TW201625943A (en) 2016-07-16
RU2016148876A (en) 2018-07-16
US20170115305A1 (en) 2017-04-27
CA2951250A1 (en) 2015-12-17
US20150355189A1 (en) 2015-12-10
CN106461610A (en) 2017-02-22
KR20170010381A (en) 2017-01-31

Similar Documents

Publication Publication Date Title
AU2015275086B2 (en) Quantitative analysis of transgenic proteins
US20240019446A1 (en) Methods and systems for selective quantitation and detection of allergens including gly m 7
AU2015301806A1 (en) Methods and systems for selective quantitation and detection of allergens
KR20190126138A (en) Optimized Target Analysis
EP2437869B2 (en) Multiplex analysis of stacked transgenic protein
US20190128896A1 (en) Methods and systems for selective quantitation and detection of allergens
Kumar Application of Mass Spectrometry in Bioprospecting
Patel The use of recently developed mass spectrometry-based proteomic approaches for the study of methylocella silvestris BL2
Brown Field asymmetric waveform ion mobility spectrometry-mass spectrometry studies of peptides and proteins

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired